These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19582593)

  • 1. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists.
    Uebele VN; Nuss CE; Fox SV; Garson SL; Cristescu R; Doran SM; Kraus RL; Santarelli VP; Li Y; Barrow JC; Yang ZQ; Schlegel KA; Rittle KE; Reger TS; Bednar RA; Lemaire W; Mullen FA; Ballard JE; Tang C; Dai G; McManus OB; Koblan KS; Renger JJ
    Cell Biochem Biophys; 2009; 55(2):81-93. PubMed ID: 19582593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.
    Kraus RL; Li Y; Gregan Y; Gotter AL; Uebele VN; Fox SV; Doran SM; Barrow JC; Yang ZQ; Reger TS; Koblan KS; Renger JJ
    J Pharmacol Exp Ther; 2010 Nov; 335(2):409-17. PubMed ID: 20682849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells.
    Uebele VN; Nuss CE; Renger JJ; Connolly TM
    J Steroid Biochem Mol Biol; 2004 Oct; 92(3):209-18. PubMed ID: 15555914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
    Yang ZQ; Barrow JC; Shipe WD; Schlegel KA; Shu Y; Yang FV; Lindsley CW; Rittle KE; Bock MG; Hartman GD; Uebele VN; Nuss CE; Fox SV; Kraus RL; Doran SM; Connolly TM; Tang C; Ballard JE; Kuo Y; Adarayan ED; Prueksaritanont T; Zrada MM; Marino MJ; Graufelds VK; DiLella AG; Reynolds IJ; Vargas HM; Bunting PB; Woltmann RF; Magee MM; Koblan KS; Renger JJ
    J Med Chem; 2008 Oct; 51(20):6471-7. PubMed ID: 18817368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of U-92032, a T-type Ca2+ channel antagonist, support a functional linkage between I(T) and slow intrathalamic rhythms.
    Porcello DM; Smith SD; Huguenard JR
    J Neurophysiol; 2003 Jan; 89(1):177-85. PubMed ID: 12522170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5beta-reduced neuroactive steroids are novel voltage-dependent blockers of T-type Ca2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo.
    Todorovic SM; Pathirathna S; Brimelow BC; Jagodic MM; Ko SH; Jiang X; Nilsson KR; Zorumski CF; Covey DF; Jevtovic-Todorovic V
    Mol Pharmacol; 2004 Nov; 66(5):1223-35. PubMed ID: 15280444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives.
    Jo MN; Seo HJ; Kim Y; Seo SH; Rhim H; Cho YS; Cha JH; Koh HY; Choo H; Pae AN
    Bioorg Med Chem; 2007 Jan; 15(1):365-73. PubMed ID: 17035033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR2 receptor ligands inhibit Cav3.2 T-type calcium channels.
    You H; Altier C; Zamponi GW
    Mol Pharmacol; 2010 Feb; 77(2):211-7. PubMed ID: 19864434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and SAR studies of a novel series of T-type calcium channel blockers.
    Park SJ; Park SJ; Lee MJ; Rhim H; Kim Y; Lee JH; Chung BY; Lee JY
    Bioorg Med Chem; 2006 May; 14(10):3502-11. PubMed ID: 16434203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-type calcium channels and tumor proliferation.
    Panner A; Wurster RD
    Cell Calcium; 2006 Aug; 40(2):253-9. PubMed ID: 16765439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead discovery and optimization of T-type calcium channel blockers.
    Park JH; Choi JK; Lee E; Lee JK; Rhim H; Seo SH; Kim Y; Doddareddy MR; Pae AN; Kang J; Roh EJ
    Bioorg Med Chem; 2007 Feb; 15(3):1409-19. PubMed ID: 17150365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation into the structure-activity relationship of novel concentration dependent, dual action T-type calcium channel agonists/antagonists.
    McCalmont WF; Patterson JR; Lindenmuth MA; Heady TN; Haverstick DM; Gray LS; Macdonald TL
    Bioorg Med Chem; 2005 Jun; 13(11):3821-39. PubMed ID: 15863008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists.
    McCalmont WF; Heady TN; Patterson JR; Lindenmuth MA; Haverstick DM; Gray LS; Macdonald TL
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3691-5. PubMed ID: 15203145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scaffold-based design and synthesis of potent N-type calcium channel blockers.
    Zamponi GW; Feng ZP; Zhang L; Pajouhesh H; Ding Y; Belardetti F; Pajouhesh H; Dolphin D; Mitscher LA; Snutch TP
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6467-72. PubMed ID: 19815411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin.
    Rimoli MG; Russo E; Cataldi M; Citraro R; Ambrosino P; Melisi D; Curcio A; De Lucia S; Patrignani P; De Sarro G; Abignente E
    Neuropharmacology; 2009 Mar; 56(3):637-46. PubMed ID: 19071141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making the T-type even tinier: corticotropin-releasing factor-mediated inhibition of low-voltage-activated calcium channel activity.
    Varela DL; Hermosilla T; Zamponi GW
    Mol Pharmacol; 2008 Jun; 73(6):1589-91. PubMed ID: 18326584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel T-type Ca2+ channel blockers.
    Jung HK; Doddareddy MR; Cha JH; Rhim H; Cho YS; Koh HY; Jung BY; Pae AN
    Bioorg Med Chem; 2004 Aug; 12(15):3965-70. PubMed ID: 15246072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist.
    Shipe WD; Barrow JC; Yang ZQ; Lindsley CW; Yang FV; Schlegel KA; Shu Y; Rittle KE; Bock MG; Hartman GD; Tang C; Ballard JE; Kuo Y; Adarayan ED; Prueksaritanont T; Zrada MM; Uebele VN; Nuss CE; Connolly TM; Doran SM; Fox SV; Kraus RL; Marino MJ; Graufelds VK; Vargas HM; Bunting PB; Hasbun-Manning M; Evans RM; Koblan KS; Renger JJ
    J Med Chem; 2008 Jul; 51(13):3692-5. PubMed ID: 18540666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats.
    Uslaner JM; Smith SM; Huszar SL; Pachmerhiwala R; Hinchliffe RM; Vardigan JD; Nguyen SJ; Surles NO; Yao L; Barrow JC; Uebele VN; Renger JJ; Clark J; Hutson PH
    Neuropharmacology; 2012 Mar; 62(3):1413-21. PubMed ID: 21110986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First pharmacophoric hypothesis for T-type calcium channel blockers.
    Doddareddy MR; Jung HK; Lee JY; Lee YS; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1605-11. PubMed ID: 15028253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.